RxDoctor Payments Data

Henry Yu, MD

Internal Medicine · Toms River, NJNPI 1891892972

Payments from drug & device makers

$314in general payments, 2019–2025

Across 7 payments — averaging $44.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • LEO Pharma Inc.$236
  • Novartis$40
  • Exact Sciences$20
  • Pfizer$18

What the payments were for

  • Food & beverage$314100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
LEO Pharma Inc.2$236
Novartis3$40
Exact Sciences1$20
Pfizer1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$314 in reported general payments places this provider in the 45th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$610,281
Medicare patients
754
Services billed
6,728

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban445$155,285
JanuviaSitagliptin Phosphate133$67,822
CreonLipase/Protease/Amylase38$47,168
SantylCollagenase Clostridium Hist.20$46,167
XareltoRivaroxaban102$45,499
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$31,643
JardianceEmpagliflozin94$29,572
FarxigaDapagliflozin Propanediol76$25,026
EntrestoSacubitril/Valsartan41$14,943
SomaCarisoprodol11$14,358
Sucralfate97$10,346
Atorvastatin Calcium628$10,014
Potassium Chloride227$8,688
MyrbetriqMirabegron27$8,664
Pantoprazole Sodium453$8,506

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$18$155,285445 claims
NovartisEntresto$40$14,94341 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Toms River

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →